Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable pharmaceutical manufacturing, provided a corporate update on January 26, 2026, detailing its 2025 activities and outlining strategic priorities for 2026. The company also confirmed plans for a pending corporate name change to Quantum Genesis AI Corp. and a corresponding trading symbol change, subject to regulatory approvals.
During 2025, Quantumzyme advanced its enzyme research and development, focusing on green chemistry applications. Key accomplishments included improvements in regulatory reporting, progress in enzyme engineering and biocatalytic process development, and the publication of U.S. and international patent applications for enzymatic processes. The company also updated its corporate website and communications to better reflect its business focus. Despite these efforts, Quantumzyme remains in the research and evaluation stage, with no assurance that patents will be granted or that intellectual property will provide commercial protection.
A significant development in 2025 was the expansion of artificial intelligence and computational research to support enzyme discovery and development. Quantumzyme began integrating machine learning techniques and computational modeling into its workflow, aiming to improve experimental design and data analysis efficiency. These AI initiatives are exploratory and intended for internal decision support, not commercial software development. The company believes that combining computational methods with laboratory research may guide future efforts, but acknowledges technical, financial, and operational limitations.
In late 2025, the Board of Directors approved a proposal to change the company's legal name to Quantum Genesis AI Corp. and seek a corresponding trading symbol change. The new name reflects a greater emphasis on computational and data-driven approaches in enzyme research. The company has submitted required documentation, and the changes are expected to be completed during the first quarter of 2026, pending FINRA approval and other regulatory requirements.
For 2026, Quantumzyme outlined several strategic priorities: continuing enzyme candidate research and evaluation; refining AI and computational tools; exploring potential partnerships with pharmaceutical and chemical companies; increasing market and stakeholder engagement through scientific forums and investor communications; and assessing long-term corporate objectives, including reporting status and capital planning. The company cautioned that these objectives are subject to risks, including technical challenges, capital availability, and market conditions.
Quantumzyme remains an early-stage biotechnology company with a focus on sustainable chemistry. More information is available at www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
